Interdisciplinary Bio Central

Korean Society for Bioinformatics (한국생명정보학회)
권호 표지
DOI QR코드

DOI QR Code

Validity of Serum Cystatin C for Prediecting Obesity Nephropathy

  • Asefy, Zahra (Department of Clinical Biochemistry, Tarbiat Modares University) ;
  • Amirrasouli, Hooshang (Department of Laboratory Medicine, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences) ;
  • Khoyi, Masood (Department of Clinical Biochemistry, Tarbiat Modares University) ;
  • Hashemi, Vida (Department of Clinical Biochemistry, Tarbiat Modares University)
  • Received : 2012.04.26
  • Accepted : 2012.05.27
  • Published : 2012.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Serum concentration of cystatin C, a marker of glomerular filtration has been associated with cardiovascular disease (CVD). The aim of this study was to evaluate cystatin C as a marker of obese patients without chronic kidney disease (CKD). Materials and Methods: The study population consisted of 36 subjects with metabolic syndrome and 32 subjects free of metabolic syndrome (the control group). HDL-C, LDL-C, blood urea, triglycerides, glucose, HbA1c, serum cystatin C and serum creatinine were measured in both groups. GFR was calculated in both groups using Cockroft-Gault equation. Results: Obese patients showed higher cystatin C levels than normal samples ($1.28{\pm}0.29$, P < 0.05). In the binary logistic regression, obese patients were significantly associated with elevated cystatin C levels. Conclusion: Our results suggest that cystatin C may be a marker for obese patients and may identify a certain degree of renal dysfunction even when serum creatinine does not exceed the normal level. In this study, we demonstrated that serum creatinineand GFR did not differ significantly between the diabetic and the control groups. Serum concentration of cystatin C was significantly higher in the diabetic group compared with the control group. The strengths of this study are the evaluation of reliability and sensivity in comparison with a 'routine test of GFR'. The methodology used allows an appropriate statistical comparison of reliability in contrast to most other previous evaluations of GFR.

Keywords

References

  1. Hu, G., Qiao, Q., Tuomilehto, J., Balkau, B., Borch-Johnsen, K., and Pyorala, K. (2004). Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164, 1066-1076. https://doi.org/10.1001/archinte.164.10.1066
  2. Azizi, F., Salehi, P., Etemadi, A., and Zahedi-Asl, S. (2003). Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 61, 29-37. https://doi.org/10.1016/S0168-8227(03)00066-4
  3. Onat, A., Ceyhan, K., Basar, O., Erer, B., Toprak, S., and Sansoy, V. (2002). Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 165, 285-292. https://doi.org/10.1016/S0021-9150(02)00236-8
  4. Gupta, A., Gupta, R., Sarna, M., Rastogi, S., Gupta, V.P., and Kothari, K. (2003). Prevalence of diabetes, impaired fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 61, 69-76. https://doi.org/10.1016/S0168-8227(03)00085-8
  5. Wisse, B.E. (2004). The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15, 2792-2800. https://doi.org/10.1097/01.ASN.0000141966.69934.21
  6. Iseki, K., Ikemiya, Y., Kinjo, K., Inoue, T., Iseki, C., Takishita, S. (2004): Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65: 1870-1876. https://doi.org/10.1111/j.1523-1755.2004.00582.x
  7. Ejerblad, E., Fored, M., Lindblad, P., Fryzek, J., McLaughlin, J.K., and Nyren, O. (2006). Obesity and risk of chronic renal failure. J Am Soc Nephrol 17, 1695-1702. https://doi.org/10.1681/ASN.2005060638
  8. Filler, G., Boken Kamp, A., Hotmann, W., Le Bricon, T., Martnez-Bru, C., and Grubb, A. (2005). Cystatin C as marker of GFR, history indication and future research. Clin Biochem 38, 1-8. https://doi.org/10.1016/j.clinbiochem.2004.09.025
  9. Henskens, Y.M.C., Veerman, E.C.I., and Nieuw Amerongen, A.V. (1996). Cystatins in health and disease. Biol Chem Hoppe-Seyler 377, 71-86.
  10. Sarnak, M.J., Katz, R., Stehman-Breen, C.O., Fried, L.F., Nancy Swords Jenny, Bruce, M.P., Newman, A., Siscovick, D., Shlipak, M; The Cardiovascular Health Study. (2005). Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults. Ann Intern Med 142, 497-505. https://doi.org/10.7326/0003-4819-142-7-200504050-00008
  11. O'Hare, A., Newman, A., Katz, R., Fried, L., Stehman-Breen, C., Seliger, S., Siscovick, D., Shlipak, M.S., and Cystatin, C. (2005). Incident peripheral arterial disease events in the elderly. Arch Intern Med 165, 2666- 2670. https://doi.org/10.1001/archinte.165.22.2666
  12. Hoehner, C.M., Greenlund, K.J., Rith-Najarian, S., Casper, M.L., and McClellan, W.M. (2002). Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter- Tribal Heart Project. J Am Soc Nephrol 13, 1626-1634. https://doi.org/10.1097/01.ASN.0000015762.92814.85
  13. Hsu, C.Y., McCulloch, C.E., Iribarren, C., Darbinian, J., and Go, A.S. (2006). Body mass index and risk for end-stage renal disease. Ann Intern Med 144, 21-28. https://doi.org/10.7326/0003-4819-144-1-200601030-00006
  14. Agnani, S., Vachharajani, V.T, Gupta, R., Atray, N.K., and Vachharajani, T.J. (2005). Does treating obesity stabilize chronic kidney disease? BMC Nephrol 6, 7. https://doi.org/10.1186/1471-2369-6-7
  15. Chagnac, A., Weinstein, T., Herman, M., Hirsh, J., Gafter, U., and Ori, Y. (2003). The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14, 1480-1486. https://doi.org/10.1097/01.ASN.0000068462.38661.89
  16. Kambham, N., Markowitz, G.S., Valeri, A.M., Lin, J., and D'Agati, V.D. (2001). Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59, 1498-1509. https://doi.org/10.1046/j.1523-1755.2001.0590041498.x
  17. Armstrong, K.A, Campbell, S.B, Hawley, C.M., Nicol, D.L, Johson, D.W., and Isbel, N.M. (2005). Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 5, 2710-2718. https://doi.org/10.1111/j.1600-6143.2005.01073.x
  18. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259, 87-91. https://doi.org/10.1126/science.7678183
  19. Wisse. B.E. (2004). The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15, 2792-2800 https://doi.org/10.1097/01.ASN.0000141966.69934.21
  20. Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., and Garg, R. (2005). Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448-1454. https://doi.org/10.1161/01.CIR.0000158483.13093.9D

Cited by

  1. Are there any new reliable markers to detect renal injury in obese children? vol.40, pp.1, 2018, https://doi.org/10.1080/0886022X.2018.1489284